Anastrozole

Small molecule

Approved / Phase 4AromataseNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
US
  • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
Product first approved 1995FDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (54)
HR+/HER2- Metastatic Breast Cancer
NCT04158362 · UNICANCER
2020-06-11 – 2032-06 · Cancer Metastatic
What this study did
NCT02947685 · Alliance Foundation Trials, LLC.
2017-06-21 – 2030-12-31 · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT05645536 · Tolmar Inc.
2022-12-28 – 2030-03 · Breast Cancer
What this study did
NCT07061717 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-07-01 – 2029-07-01 · Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
What this study did
NCT02763566 · Eli Lilly and Company
2016-12-05 – 2028-03 · Breast Cancer
What this study did
NCT04906395 · Tolmar Inc.
2021-07-01 – 2027-01-30 · Breast Cancer
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT00887380 · Trans Tasman Radiation Oncology Group
2009-09-16 – 2024-12 · Breast Cancer
What this study did
NCT02097459 · Peking Union Medical College Hospital
2014-03 – 2024-03 · Breast Cancer
What this study did
NCT03966898 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-19 – 2023-12-30 · Advanced Breast Cancer
What this study did
NCT00253422 · Institute of Cancer Research, United Kingdom
2004-03-26 – 2022-11-28 · Breast Cancer
What this study did
NCT00078832 · Queen Mary University of London
2003-09 – 2021-05-31 · Breast Cancer
What this study did
NCT02137837 · SWOG Cancer Research Network
2014-05 – 2019-12-31 · Breast Cancer
What this study did
NCT00295646 · Austrian Breast & Colorectal Cancer Study Group
1999-06 – 2018-06-26 · Breast Cancer
What this study did
NCT01402193 · Fudan University
2011-07 – 2015-07 · Breast Cancer
What this study did
NCT00893061 · Centre Oscar Lambret
2009-03-16 – 2014-11-26 · Breast Cancer
What this study did
NCT00902954 · Fudan University
2008-03 – 2011-06 · Breast Cancer
What this study did
NCT00143390 · Pfizer
2005-04 – 2010-12 · Breast Neoplasms
What this study did
NCT00849030 · AstraZeneca
1996-07 – 2010-04 · Breast Cancer
What this study did
NCT00232661 · AstraZeneca
2000-08 – 2007-12 · Breast Cancer
What this study did
NCT00286117 · AstraZeneca
1998-03 – 2006-05 · Breast Cancer
What this study did
NCT00814125 · AstraZeneca
1997-06 – 2005-12 · Breast Cancer
What this study did
NCT00635713 · AstraZeneca
1997-05 – 2004-09 · Advanced Breast Cancer
What this study did
NCT00784862 · AstraZeneca
1998-06 – 1999-03 · Breast Cancer
What this study did
Other / comorbidity
NCT06223698 · Region Örebro County
2025-05-02 – 2035-05-02 · Breast Cancer
What this study did
NCT06492616 · Stemline Therapeutics, Inc.
2024-09-27 – 2032-10 · Breast Cancer
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
NCT07391774 · National Cancer Institute (NCI)
2026-08-10 – 2029-07-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
What this study did
NCT05586802 · Georgios Papadakis
2023-03-21 – 2027-04-30 · Klinefelter Syndrome
What this study did
NCT01953588 · Alliance for Clinical Trials in Oncology
2014-02-27 – 2027-04-01 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT01272037 · National Cancer Institute (NCI)
2011-02-28 – 2027-01-08 · Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
What this study did
NCT05780567 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-03-30 – 2027-01 · Breast Cancer
What this study did
NCT00301457 · Maastricht University Medical Center
2006-06 – 2022-04 · Breast Cancer
What this study did
NCT00072462 · Queen Mary University of London
2003-09 – 2021-05-31 · Breast Cancer
What this study did
NCT00265759 · Alliance for Clinical Trials in Oncology
2006-01 – 2019-11-27 · Breast Cancer
What this study did
NCT02995772 · Dharmais National Cancer Center Hospital
2011-11 – 2018-11 · Breast Cancer
What this study did
NCT00295620 · AstraZeneca
2004-03-01 – 2017-06-30 · Breast Cancer
What this study did
NCT00053898 · NSABP Foundation Inc
2003-01 – 2016-05 · Breast Cancer
What this study did
NCT00440180 · University of Utah
2007-03 – 2014-06 · Obesity, Oligospermia
What this study did
NCT00944918 · AstraZeneca
2008-12 – 2011-06 · Progression-free Survival
What this study did
NCT00605267 · AstraZeneca
2007-10 – 2010-12 · Breast Cancer
What this study did
NCT00519883 · British Columbia Cancer Agency
2007-12 – 2010-07 · Musculoskeletal Symptoms
What this study did
NCT00291759 · AstraZeneca
1996-01 – 2009-06 · Breast Cancer
What this study did
NCT00300508 · AstraZeneca
started 1996-01 · Breast Neoplasms
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00133354 · Nemours Children's Clinic
2001-11 – 2010-08 · Hypopituitarism
What this study did
Phase 2 (102)
HR+/HER2- Metastatic Breast Cancer
NCT05501704 · Jose Pablo Leone
2023-10-11 – 2036-04-01 · Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
What this study did
NCT07716046 · Fudan University
2026-10-01 – 2032-12-31 · Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer, HR+/HER2+ Breast Cancer
What this study did
NCT05524584 · University of California, Irvine
2022-08-31 – 2031-12-31 · Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06953882 · Yale University
2025-07-09 – 2030-09 · HER2 Negative Breast Cancer
What this study did
NCT06086704 · University of Wisconsin, Madison
2024-09-25 – 2030-08-31 · Breast Cancer
What this study did
NCT05467891 · Oana Danciu
2022-09-13 – 2029-08-15 · Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT02942355 · Wake Forest University Health Sciences
2016-12-07 – 2028-06-30 · Female Breast Carcinoma, Breast Cancer
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT04886531 · Ruth O'Regan
2022-07-21 – 2027-12-21 · Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
What this study did
NCT05190094 · International Cancer Research Group, United Arab Emirates
2022-12-20 – 2026-06 · Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
What this study did
NCT04719273 · Thomas Jefferson University
2021-01-28 – 2025-12-17 · Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
What this study did
NCT06957379 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-29 – 2025-12 · HR+/HER2- Advanced/Metastatic Breast Cancer
What this study did
NCT03822468 · Novartis Pharmaceuticals
2019-06-11 – 2024-08-30 · Breast Cancer
What this study did
NCT02206984 · Priscilla McAuliffe
2015-09-30 – 2024-07-19 · Breast Cancer
What this study did
NCT02188745 · Dartmouth-Hitchcock Medical Center
2016-03-11 – 2024-07-05 · Metastatic Breast Cancer
What this study did
NCT02648477 · City of Hope Medical Center
2016-03-28 – 2023-12-30 · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
What this study did
NCT00921115 · University of Kansas Medical Center
2009-05 – 2023-03-20 · Invasive Breast Cancer
What this study did
NCT02894398 · iOMEDICO AG
2016-09-06 – 2023-02-15 · Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
What this study did
NCT03691493 · Emory University
2019-02-08 – 2022-10-13 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03555877 · GBG Forschungs GmbH
2018-03-15 – 2022-07-21 · Breast Cancer Metastatic
What this study did
NCT02440230 · Shanghai Jiao Tong University School of Medicine
2015-05 – 2021-12 · Breast Cancer
What this study did
NCT02269670 · Emory University
2014-11-25 – 2021-01-25 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT03874325 · H. Lee Moffitt Cancer Center and Research Institute
2019-04-26 – 2021-01-06 · Breast Cancer, Hormone Receptor Positive Tumor
What this study did
NCT01266213 · Samsung Medical Center
2010-12 – 2019-12 · Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
What this study did
NCT01989780 · Japan Breast Cancer Research Group
2014-01 – 2019-06 · Metastatic Breast Cancer
What this study did
NCT02291913 · SCRI Development Innovations, LLC
2014-12-18 – 2019-01-31 · Breast Cancer
What this study did
NCT00570323 · Mothaffar Rimawi
2007-12 – 2018-12-05 · Breast Cancer
What this study did
NCT02585388 · ARCAGY/ GINECO GROUP
2015-10-23 – 2017-05-15 · Breast Cancer
What this study did
NCT02549430 · Fondazione Sandro Pitigliani
2012-10 – 2017-02-09 · Breast Cancer
What this study did
NCT02072512 · Hospital Affiliated to Military Medical Science, Beijing
2014-01 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT02000596 · University of Maryland, Baltimore
2014-01 – 2016-01 · Metastatic Breast Cancer
What this study did
NCT00661531 · Georgetown University
2008-04 – 2015-06 · Breast Cancer, Cancer of the Breast, Neoplasms, Breast
What this study did
NCT00128843 · Spanish Breast Cancer Research Group
2001-08 – 2014-10 · Breast Cancer
What this study did
NCT01972984 · Ottawa Hospital Research Institute
2012-10 – 2014-08 · Breast Cancer
What this study did
NCT00555477 · University of Michigan Rogel Cancer Center
2007-08 – 2013-09 · Breast Cancer
What this study did
NCT00186121 · Stanford University
2000-10 – 2013-06 · Breast Cancer
What this study did
NCT00057941 · National Cancer Institute (NCI)
2003-09 – 2012-06 · Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00405938 · SCRI Development Innovations, LLC
2006-11 – 2011-06 · Breast Cancer, Breast Neoplasms
What this study did
NCT00687648 · National Cancer Centre, Singapore
2008-05 – 2010-04 · Breast Cancer
What this study did
NCT00005908 · National Cancer Institute (NCI)
2000-06 – 2008-01 · Breast Cancer, Breast Neoplasm
What this study did
NCT00049062 · The University of Texas Health Science Center at San Antonio
2002-09 – 2007-10 · Breast Cancer
What this study did
NCT00303615 · Legacy Health System
2005-06 – 2007-07 · Metastatic Breast Cancer
What this study did
NCT00217659 · SWOG Cancer Research Network
2005-09 – 2007-01 · Breast Cancer
What this study did
NCT00235937 · AstraZeneca
2001-12 – 2006-12 · Breast Cancer
What this study did
NCT00206414 · Baylor Breast Care Center
2003-01 – 2006-09 · BREAST CANCER
What this study did
Phase 1/2 (9)
HR+/HER2- Metastatic Breast Cancer
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT03304080 · Icahn School of Medicine at Mount Sinai
2017-12-20 – 2027-12-31 · Breast Neoplasms, Breast Diseases
What this study did
NCT04539496 · Sihuan Pharmaceutical Holdings Group Ltd.
2018-05-22 – 2025-12-31 · Metastasis Solid Tumors, Advanced Breast Cancer
What this study did
NCT02730923 · Centre Leon Berard
2016-04 – 2024-12 · Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor
What this study did
NCT03481998 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-22 – 2022-07-30 · Advanced Breast Cancer
What this study did
NCT01791985 · Imperial College London
2012-07 – 2018-12 · Breast Cancer
What this study did
NCT00217399 · National Cancer Institute (NCI)
2005-06 – 2013-01 · Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
Other / comorbidity
NCT01216176 · Joyce Marie Slingerland, MD
2008-10-21 – 2018-02-07 · Breast Cancer
What this study did
NCT01215292 · University of Washington
2011-01 – 2012-03 · Healthy Males
What this study did
Phase 1 (33)
HR+/HER2- Metastatic Breast Cancer
NCT04316169 · Medical College of Wisconsin
2021-10-21 – 2028-01 · Solid Tumor, Advanced Breast Cancer
What this study did
NCT03616587 · AstraZeneca
2018-10-11 – 2027-06-24 · ER+ HER2- Advanced Breast Cancer
What this study did
NCT04556773 · AstraZeneca
2020-12-17 – 2027-06-01 · Metastatic Breast Cancer
What this study did
NCT07163481 · Hunan Cancer Hospital
2025-10 – 2026-12 · Stage IV (Metastatic) Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT02779751 · Eli Lilly and Company
2016-11-14 – 2026-12 · Non Small Cell Lung Cancer, Breast Cancer
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT01597193 · Pfizer
2012-04-30 – 2018-01-22 · Breast Cancer
What this study did
NCT01344031 · National Cancer Institute (NCI)
2011-04-21 – 2011-07-01 · Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
Other / comorbidity
NCT07604272 · Northwestern University
2026-10-02 – 2028-07 · Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or Gangrene
What this study did
NCT04757532 · Parc de Salut Mar
2020-12-03 – 2021-03-10 · Healthy Volunteers
What this study did
NCT04445922 · The Affiliated Hospital of Qingdao University
2020-07-04 – 2020-10-30 · Healthy Volunteers
What this study did
NCT04438733 · The Affiliated Hospital of Qingdao University
2020-06-18 – 2020-09-30 · Healthy Volunteers
What this study did
NCT02476955 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2015-06-09 – 2019-05-07 · Solid Tumors, Ovarian Cancer, Endometrial Cancer
What this study did
NCT01862835 · Mayo Clinic
2013-05 – 2018-12-30 · Normal Healthy Volunteers
What this study did
NCT03314298 · Havah Therapeutics Pty Ltd
2017-08-14 – 2018-04-17 · Mammographic Density
What this study did
NCT03264651 · Havah Therapeutics Pty Ltd
2017-02-01 – 2018-03-21 · Mammographic Density
What this study did
NCT01763541 · Massachusetts General Hospital
2014-06 – 2016-02 · Hypertension
What this study did
NCT02026973 · Mayo Clinic
2014-03 – 2015-11 · Normal Healthy Volunteers
What this study did
NCT01568281 · AstraZeneca
2012-04 – 2012-06 · Safety, Pharmacokinetics
What this study did
NCT03118479 · Massachusetts General Hospital
2010-05 – 2010-09-01 · Hypogonadotropic Hypogonadism, Kallmann Syndrome
What this study did
NCT00438321 · Massachusetts General Hospital
2006-09 – 2010-02-26 · Metabolic Syndrome
What this study did
NCT00588003 · Memorial Sloan Kettering Cancer Center
2004-03 – 2009-11 · Breast Cancer
What this study did
NCT00309855 · Mayo Clinic
2005-12 – 2008-08 · Aging
What this study did
NCT01155947 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-07 · Healthy
What this study did
NCT01155960 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-07 · Healthy
What this study did
NCT01183390 · Teva Pharmaceuticals USA
2005-09 – 2005-10 · Healthy
What this study did
NCT01182181 · Teva Pharmaceuticals USA
2005-08 – 2005-09 · Healthy
What this study did
Phase 4 (17)
HR+/HER2- Metastatic Breast Cancer
NCT05161195 · Novartis Pharmaceuticals
2022-07-07 – 2030-08-14 · Metastatic Breast Cancer
What this study did
NCT03220178 · Palleos Healthcare GmbH
2017-07-24 – 2021-12-07 · Breast Neoplasm
What this study did
NCT00126360 · St George Hospital, Australia
2005-08 – 2016-05 · Breast Cancer
What this study did
NCT01612871 · Institut Claudius Regaud
2012-06-27 – 2016-01-28 · Breast Cancer
What this study did
NCT01553903 · Institut Claudius Regaud
2011-12 – 2013-05 · Breast Cancer
What this study did
NCT00537771 · AstraZeneca
2007-09 – 2011-12 · Breast Cancer
What this study did
NCT00544986 · AstraZeneca
2005-06 – 2007-11 · Breast Cancer
What this study did
Other / comorbidity
NCT03490513 · Baylor College of Medicine
2018-05-01 – 2026-06-30 · Hypogonadism, Hypogonadotropic, Obesity
What this study did
NCT06253702 · University of Wisconsin, Madison
2024-07-24 – 2025-05-31 · Cerebrovascular Disorders
What this study did
NCT03238703 · Fred Hutchinson Cancer Center
2018-09-01 – 2025-03-14 · HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
What this study did
NCT02089854 · Peking Union Medical College Hospital
2014-11 – 2019-04 · Female Breast Cancer
What this study did
NCT02959853 · Baylor College of Medicine
2016-06 – 2018-12-20 · Hypogonadism, Severe Obesity
What this study did
NCT02137538 · Stanford University
2009-11-18 – 2018-06-05 · Short Stature
What this study did
NCT01769781 · Centre for Endocrinology and Reproductive Medicine, Italy
2013-01 – 2015-07 · Endometriosis
What this study did
NCT00323479 · AstraZeneca
2006-06 – 2009-01 · Early Breast Cancer
What this study did
NCT00082277 · AstraZeneca
2004-04 – 2007-10 · Breast Cancer
What this study did
NCT00286351 · Rigshospitalet, Denmark
started 2005-01 · Endometriosis
What this study did
Early phase / not applicable (21)
HR+/HER2- Metastatic Breast Cancer
NCT06235931 · Second Affiliated Hospital of Soochow University
2024-02-01 – 2026-12-01 · Breast Neoplasms
What this study did
NCT05167643 · Tianjin Medical University Cancer Institute and Hospital
2022-01-23 – 2024-08-23 · Advanced HR+ HER2 Negative Breast Carcinoma
What this study did
NCT01720602 · University of Washington
2012-11 – 2020-01 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01153672 · University of Washington
2010-11 – 2016-08-11 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00612560 · Roswell Park Cancer Institute
2007-11 – 2014-04 · Breast Cancer
What this study did
NCT01004744 · Columbia University
2007-07 – 2009-08 · Invasive Breast Cancer
What this study did
NCT01016665 · Federal University of São Paulo
2005-04 – 2008-06 · Breast Cancer
What this study did
NCT01155089 · Roxane Laboratories
2006-05 – 2006-06 · Breast Cancer
What this study did
NCT01155102 · Roxane Laboratories
2006-04 – 2006-05 · Breast Cancer
What this study did
Other / comorbidity
NCT07568574 · Enhanced Emirates Limited
2026-03-12 – 2033-03-01 · Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
What this study did
NCT07212712 · University of British Columbia
2026-04-01 – 2027-12-31 · Cerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences, Exercise, Vascular
What this study did
NCT01824836 · ECOG-ACRIN Cancer Research Group
2013-06-11 – 2026-12 · Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT02095184 · University of Maryland, Baltimore
2015-05-25 – 2024-08-02 · Breast Cancer
What this study did
NCT02758431 · University of Colorado, Denver
2016-07-01 – 2023-01-04 · Hypogonadism
What this study did
NCT01520467 · Assistance Publique - Hôpitaux de Paris
2012-04 – 2016-10 · Silver Russell Syndrome, Prader-Willi Syndrome
What this study did
NCT02269072 · Massachusetts General Hospital
2015-02 – 2016-02 · Hypertension
What this study did
NCT00641303 · University of Maryland, Baltimore
2008-05 – 2011-11 · Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
What this study did
NCT00433173 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2006-05 – 2011-03 · Metabolic Syndrome
What this study did
NCT00983554 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005-06 – 2009-10 · Obesity, Insulin Resistance
What this study did
NCT01105299 · Asan Medical Center
2008-06 – 2008-08 · Healthy
What this study did
NCT00437853 · Instituto Nacional de Cancerologia de Mexico
2003-06 – 2007-02 · Breast Cancer
What this study did
Used as active comparator (30)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (17)
HR+/HER2- Metastatic Breast Cancer
NCT07894328 · Jiangsu HengRui Medicine Co., Ltd.
2026-11-20 – 2031-09-30 · Breast Cancer
What this study did
NCT04964934 · AstraZeneca
2021-06-30 – 2028-09-01 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT06016738 · Olema Pharmaceuticals, Inc.
2023-11-16 – 2028-02-29 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
What this study did
NCT07024173 · Shandong Suncadia Medicine Co., Ltd.
2025-07-23 – 2027-12 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01602380 · AstraZeneca
2012-10-17 – 2026-01-16 · Hormone Receptor Positive Breast Cancer
What this study did
Other / comorbidity
NCT05952557 · AstraZeneca
2023-10-05 – 2037-05-06 · Breast Cancer, Early Breast Cancer
What this study did
NCT05774951 · AstraZeneca
2023-03-31 – 2036-05-29 · Breast Cancer, Early Breast Cancer
What this study did
NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC
2023-12-15 – 2035-11-01 · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
NCT07190443 · Japanese Foundation for Cancer Research
2025-02-07 – 2035-02-06 · Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
What this study did
NCT07349069 · Shandong Suncadia Medicine Co., Ltd.
2026-03-04 – 2034-01 · Breast Cancer
What this study did
NCT05514054 · Eli Lilly and Company
2022-10-04 – 2032-03 · Breast Neoplasms
What this study did
NCT06671912 · Alliance for Clinical Trials in Oncology
2025-02-19 – 2031-11-30 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT06072781 · Verastem, Inc.
2024-03-18 – 2031-02-09 · Low Grade Serous Ovarian Cancer
What this study did
NCT04134598 · Azienda Ospedaliero-Universitaria Careggi
2021-02-08 – 2030-03-31 · Breast Cancer
What this study did
NCT00248170 · Novartis Pharmaceuticals
2005-12 – 2014-09 · Breast Cancer
What this study did
NCT00066573 · NCIC Clinical Trials Group
2003-06-06 – 2012-01-06 · Breast Cancer
What this study did
Phase 2 (13)
HR+/HER2- Metastatic Breast Cancer
NCT07729046 · University of California, San Diego
2027-07 – 2035-06 · Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
What this study did
NCT04985266 · Royal Marsden NHS Foundation Trust
2022-03-30 – 2030-09-01 · ER+ Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT04059484 · Sanofi
2019-10-22 – 2025-01-02 · Breast Cancer Metastatic
What this study did
NCT05549505 · Arvinas Inc.
2023-02-15 – 2024-07-25 · Breast Cancer
What this study did
NCT00738777 · The Netherlands Cancer Institute
2008-07 – 2024-06 · Breast Cancer
What this study did
NCT04256941 · M.D. Anderson Cancer Center
2019-05-31 – 2023-09-22 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03024580 · Instituto Nacional de Cancer, Brazil
2017-03-06 – 2020-09 · Breast Neoplasm
What this study did
NCT00871858 · Institut Bergonié
2008-03-18 – 2018-07-02 · Breast Cancer
What this study did
NCT00274469 · AstraZeneca
2006-02-06 – 2017-01-13 · Metastatic Breast Cancer
What this study did
NCT00728949 · Eli Lilly and Company
2008-08 – 2015-02 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT05472792 · UNC Lineberger Comprehensive Cancer Center
2022-05-17 – 2032-04-15 · Breast Cancer, Quality of Life
What this study did
NCT05896566 · ETOP IBCSG Partners Foundation
2024-01-23 – 2025-09-18 · Breast Cancer
What this study did
Appears in other studies (25)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (13)
HR+/HER2- Metastatic Breast Cancer
NCT06507618 · University of Virginia
2024-07-19 – 2034-03-01 · Breast Cancer Female
What this study did
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT04584853 · Institute of Cancer Research, United Kingdom
2020-12-23 – 2030-10 · Breast Cancer Female
What this study did
NCT05257395 · Xuanzhu Biopharmaceutical Co., Ltd.
2022-03-14 – 2030-09-05 · Advanced Breast Cancer
What this study did
NCT01674140 · SWOG Cancer Research Network
2013-09-12 – 2030-01 · Breast Cancer
What this study did
NCT02246621 · Eli Lilly and Company
2014-11-06 – 2026-12 · Breast Cancer
What this study did
NCT02278120 · Novartis Pharmaceuticals
2014-11-20 – 2023-04-20 · Advanced Metastatic Breast Cancer
What this study did
NCT00075764 · SWOG Cancer Research Network
2004-04 – 2018-10-01 · Breast Cancer
What this study did
NCT00543127 · Spanish Breast Cancer Research Group
2007-11 – 2016-07 · Breast Cancer
What this study did
NCT00256698 · AstraZeneca
2004-01 – 2012-02 · Breast Cancer
What this study did
NCT00327769 · AstraZeneca
2005-11 – 2007-09 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT00310180 · National Cancer Institute (NCI)
2006-04-07 – 2030-09-30 · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
What this study did
NCT02918084 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2013-06 – 2028-06 · Breast Cancer
What this study did
Phase 2/3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT00684216 · The Netherlands Cancer Institute
2008-04 – 2013-05 · Breast Cancer
What this study did
Phase 2 (9)
HR+/HER2- Metastatic Breast Cancer
NCT03671330 · Novartis Pharmaceuticals
2018-08-29 – 2025-05-09 · Breast Cancer
What this study did
NCT02140437 · Fudan University
2014-03 – 2016-06 · Carcinoma Breast Stage IV
What this study did
NCT01151215 · AstraZeneca
2010-06 – 2013-01 · Neoplasms, Breast Neoplasms, Breast Cancer
What this study did
NCT00081510 · Merck Sharp & Dohme LLC
2003-12 – 2009-05 · Breast Cancer
What this study did
NCT00066378 · European Organisation for Research and Treatment of Cancer - EORTC
2003-05 – 2007-08 · Breast Cancer
What this study did
Other / comorbidity
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT04272801 · Shayna Showalter, MD
2020-04-07 – 2026-06-01 · Breast Cancer Female
What this study did
NCT00481845 · Stanford University
2008-01 – 2009-12 · Breast Cancer
What this study did
NCT00357110 · AstraZeneca
2006-04 – 2008-10 · Breast Cancer
What this study did
Phase 1 (1)
HR+/HER2- Metastatic Breast Cancer
NCT05307705 · Eli Lilly and Company
2022-05-11 – 2026-12 · Breast Cancer
What this study did
Phase 4 (1)
Other / comorbidity
NCT01127295 · Institut Claudius Regaud
2010-06-17 – 2017-12-01 · Hormono-depending Adjuvant Breast Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Anastrozole: this drugApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
ZovegalisibPhase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 43 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(34 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Anastrozole to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-22 · NCT04886531 · CT.gov ↗
What to watch
Phase 2Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer …Recruiting
Est. primary completion 2026-12-31 · NCT04553770 · CT.gov ↗
What to watch
Early phase / not applicableCerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences, Exercise, VascularNot yet recruiting
Est. primary completion 2026-12-31 · NCT07212712 · CT.gov ↗
What to watch
2027 (10)
January 2027 (2)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-30 · NCT04906395 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the BreastRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
April 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
Phase 3Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma …Active not recruiting
Est. primary completion 2027-04-01 · NCT01953588 · CT.gov ↗
What to watch
Phase 3Klinefelter SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT05586802 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Breast Cancer, Cancer of the BreastRecruiting
Est. primary completion 2027-11-30 · NCT05837455 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-12 · NCT07935317 · CT.gov ↗
What to watch
2028 (8)
May 2028 (2)
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT02942355 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or GangreneRecruiting
Est. primary completion 2028-07 · NCT07604272 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-31 · NCT06086704 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Ductal Carcinoma in SituRecruiting
Est. primary completion 2028-11 · NCT06075953 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗
What to watch
2029 (4)
July 2029 (2)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
Phase 3Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases, CDK4/6 Inhibitor, HR+/HER2- Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07581834 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch

See the full readout calendar ↗